col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

805 Results       Page 1

Springer-Verlag: Reactions Weekly
  original article Date Title Authors   All Authors
1 [GO] 2023―Sep―18 COVID-19 vaccination does not increase risk of preterm labour
2 [GO] 2023―Sep―18 Safety signal of CIDP with use of AstraZeneca COVID-19 vaccine
3 [GO] 2023―Sep―18 COVID-19-vaccine
4 [GO] 2023―Sep―18 Covid-19-vaccine
5 [GO] 2023―Sep―18 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
6 [GO] 2023―Sep―18 Covid-19-vaccine-pfizer-biontech
7 [GO] 2023―Sep―18 COVID-19-vaccines
8 [GO] 2023―Sep―08 Antibacterial use prior to COVID-19 vaccination increases risk of COVID-19 infection
9 [GO] 2023―Sep―08 Shoulder injury after Pfizer-BioNTech COVID-19 vaccine
10 [GO] 2023―Sep―08 COVID-19 vaccine/nirmatrelvir+ritonavir
11 [GO] 2023―Sep―01 COVID-19 vaccines/immunosuppressants/Varicella zoster virus vaccine
12 [GO] 2023―Sep―01 Sars-cov-2-vaccine-inactivated-sinovac-biotech
13 [GO] 2023―Aug―25 Low risk of urticaria exacerbation following COVID-19 vaccination
14 [GO] 2023―Aug―25 COVID-19 vaccine
15 [GO] 2023―Aug―25 Pfizer-BioNTech COVID-19 vaccine increases risk of myocarditis/pericarditis
16 [GO] 2023―Aug―25 AEs and rheumatic disease flares after COVID-19 vaccine versus influenza vaccine
17 [GO] 2023―Aug―25 Novavax COVID-19 vaccine: no new safety concerns
18 [GO] 2023―Aug―25 COVID-19-vaccine
19 [GO] 2023―Aug―25 COVID-19-vaccine
20 [GO] 2023―Aug―25 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
21 [GO] 2023―Aug―25 COVID-19-Vaccine-Pfizer-BioNTech
22 [GO] 2023―Aug―18 Bivalent mRNA COVID-19 booster vaccines safe in adults
23 [GO] 2023―Aug―18 Co-administered influenza vaccine and mRNA COVID-19 vaccine safe
24 [GO] 2023―Aug―18 COVID-19-vaccine
25 [GO] 2023―Aug―18 COVID-19-vaccines/methylprednisolone
26 [GO] 2023―Aug―18 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
27 [GO] 2023―Aug―11 Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD
28 [GO] 2023―Aug―11 No association between mRNA COVID-19 vaccines and menorrhagia
29 [GO] 2023―Aug―04 Covid-19-vaccine
30 [GO] 2023―Jul―28 Covid-19-vaccine
31 [GO] 2023―Jul―28 COVID-19-vaccine
32 [GO] 2023―Jul―28 COVID-19-vaccines/disease-modifying-antirheumatics interaction
33 [GO] 2023―Jul―28 Severe acute respiratory syndrome coronavirus 2 mrna vaccine
34 [GO] 2023―Jul―21 Societal burden of opioid toxicity-related deaths in the US worsened during COVID-19 pandemic
35 [GO] 2023―Jul―21 Immediate ADRs after COVID-19 vaccination in Denmark
36 [GO] 2023―Jul―21 Novavax COVID-19 vaccine NVX-CoV2373 safe in older adults
37 [GO] 2023―Jul―21 COVID-19 vaccine-related autoimmune haemolytic anaemia
38 [GO] 2023―Jul―21 COVID-19 vaccine-related menstruation disorders
39 [GO] 2023―Jul―21 Covid-19-vaccine/immune-globulin
40 [GO] 2023―Jul―21 Sars-cov-2-vaccine-inactivated-sinovac-biotech
41 [GO] 2023―Jul―14 No major differences in AEs between COVID-19 vaccination schedules
42 [GO] 2023―Jul―14 EMA endorses statement on safety of COVID-19 vaccines issued by ICMRA
43 [GO] 2023―Jul―14 COVID-19-vaccine/dexamethasone/tocilizumab
44 [GO] 2023―Jul―14 SARS-COV-2-vaccine-inactivated-sinovac-biotech/tozinameran
45 [GO] 2023―Jul―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech/zf-2001
46 [GO] 2023―Jul―07 COVID-19 vaccine-related hypersensitivity: basophil reactivity
47 [GO] 2023―Jul―07 EMA publishes report on ensuring safety of COVID-19 vaccines
48 [GO] 2023―Jul―07 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
49 [GO] 2023―Jul―07 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
50 [GO] 2023―Jun―30 COVID-19-vaccine
51 [GO] 2023―Jun―30 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
52 [GO] 2023―Jun―30 Covid-19-vaccine
53 [GO] 2023―Jun―30 Sars-cov-2-vaccine-inactivated-sinovac-biotech
54 [GO] 2023―Jun―23 Covid-19-vaccine/fondaparinux-sodium
55 [GO] 2023―Jun―23 COVID-19 vaccination and cyclophosphamide
56 [GO] 2023―Jun―23 Transverse myelitis after COVID-19 vaccination
57 [GO] 2023―Jun―23 Sars-cov-2-vaccine-inactivated-sinovac-biotech
58 [GO] 2023―Jun―23 Sars-cov-2-vaccine-inactivated-sinovac-biotech
59 [GO] 2023―Jun―16 Covid-19-vaccine
60 [GO] 2023―Jun―16 Covid-19-vaccine
61 [GO] 2023―Jun―16 COVID-19 vaccines
62 [GO] 2023―Jun―16 Third mRNA COVID-19 vaccine dose well tolerated in infants and young children
63 [GO] 2023―Jun―16 Sars-cov-2-vaccine-inactivated-sinovac-biotech
64 [GO] 2023―Jun―09 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
65 [GO] 2023―Jun―09 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/dabigatran-etexilate/dipyrone
66 [GO] 2023―Jun―09 Sars-cov-2-vaccine-inactivated-sinovac-biotech
67 [GO] 2023―Jun―02 Covid-19-vaccine
68 [GO] 2023―Jun―02 Covid-19-vaccine
69 [GO] 2023―Jun―02 Covid-19-vaccine
70 [GO] 2023―Jun―02 BNT162b2 COVID-19 vaccine safe in children, signal for myocarditis/pericarditis in adolescents
71 [GO] 2023―May―26 COVID-19-vaccine
72 [GO] 2023―May―18 Covid-19-vaccine/nirmatrelvir+ritonavir/tacrolimus
73 [GO] 2023―May―18 Covid-19-vaccine
74 [GO] 2023―May―18 Nirmatrelvir+ritonavir-related AEs in patients with COVID-19 infections
75 [GO] 2023―May―18 Associations between COVID-19 vaccination and menstruation disorders "weak and inconsistent"
76 [GO] 2023―May―18 Sars-cov-2-vaccine-inactivated-sinovac-biotech
77 [GO] 2023―May―18 SARS-COV-2-vaccine-inactivated-sinovac-biotech
78 [GO] 2023―May―12 Covid-19-vaccine
79 [GO] 2023―May―12 Covid-19-vaccine
80 [GO] 2023―May―12 COVID-19-vaccine/dexamethasone
81 [GO] 2023―May―12 Covid-19-vaccine
82 [GO] 2023―May―12 Long-term safety of AstraZeneca COVID-19 vaccine
83 [GO] 2023―May―05 COVID-19-vaccines
84 [GO] 2023―May―05 COVID-19 vaccine-related ADRs in children and adolescents
85 [GO] 2023―May―05 COVID-19 vaccine in adolescents: no new serious safety concerns identified
86 [GO] 2023―May―05 Viral vector-based COVID-19 vaccines: risk of thrombosis with thrombocytopenia
87 [GO] 2023―May―05 Sars-cov-2-vaccine-inactivated-sinovac-biotech
88 [GO] 2023―Apr―28 COVID-19-vaccines
89 [GO] 2023―Apr―28 COVID-19-vaccine/nivolumab
90 [GO] 2023―Apr―28 Sars-cov-2-vaccine-inactivated-sinovac-biotech
91 [GO] 2023―Apr―28 Sars-cov-2-vaccine-inactivated-sinovac-biotech
92 [GO] 2023―Apr―28 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
93 [GO] 2023―Apr―21 COVID-19-vaccines
94 [GO] 2023―Apr―21 Covid-19-vaccine
95 [GO] 2023―Apr―21 Covid-19 vaccines
96 [GO] 2023―Apr―21 Vulval aphthous ulcers in adolescents after COVID-19 vaccination
97 [GO] 2023―Apr―21 mRNA COVID-19 vaccination not associated with retinal vascular occlusion
98 [GO] 2023―Apr―14 COVID-19-vaccines/glucocorticoids
99 [GO] 2023―Apr―14 Covid-19-vaccine/nirmatrelvir/ritonavir
100 [GO] 2023―Apr―14 COVID-19-vaccine/elasomeran
101 [GO] 2023―Apr―14 Covid-19 vaccine
102 [GO] 2023―Apr―14 COVID-19 vaccination: serious AEs and AESIs rare
103 [GO] 2023―Apr―06 Covid-19-vaccine
104 [GO] 2023―Apr―06 COVID-19 vaccination safety during pregnancy
105 [GO] 2023―Apr―06 Experiences after first COVID-19 vaccination impact severity of AEs after second dose
106 [GO] 2023―Apr―06 SARS-Cov-2-vaccine-inactivated-Sinovac-Biotech
107 [GO] 2023―Apr―06 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
108 [GO] 2023―Mar―31 Covid-19-vaccine
109 [GO] 2023―Mar―31 Covid-19-vaccine
110 [GO] 2023―Mar―31 COVID-19-vaccine
111 [GO] 2023―Mar―31 SARS-COV-2-vaccine-inactivated
112 [GO] 2023―Mar―31 Sars-cov-2-vaccine-inactivated-sinovac-biotech
113 [GO] 2023―Mar―25 Covid-19-vaccine/elasomeran/tozinameran
114 [GO] 2023―Mar―25 Covid-19-vaccine/obinutuzumab
115 [GO] 2023―Mar―25 Covid-19-vaccine-pfizer-biontech
116 [GO] 2023―Mar―25 COVID-19-vaccine
117 [GO] 2023―Mar―25 Covid-19 vaccine
118 [GO] 2023―Mar―23 Covid-19-vaccine
119 [GO] 2023―Mar―23 Covid-19-vaccine
120 [GO] 2023―Mar―23 COVID-19-vaccine
121 [GO] 2023―Mar―23 Covid-19-vaccine
122 [GO] 2023―Mar―23 COVID-19 vaccine-related Guillain-Barre syndrome
123 [GO] 2023―Mar―10 COVID-19 vaccine
124 [GO] 2023―Mar―10 Anxiety and depression increase risk of reporting COVID-19 vaccine-related AEs
125 [GO] 2023―Mar―10 Covid-19-vaccine
126 [GO] 2023―Mar―10 Sars-cov-2 vaccine-inactivated-sinovac-biotech
127 [GO] 2023―Mar―10 SARS-COV-2-vaccine-inactivated-sinovac-biotech
128 [GO] 2023―Mar―03 African countries report fewer AEFIs after COVID-19 vaccination than RoW
129 [GO] 2023―Mar―03 COVID-19 vaccine
130 [GO] 2023―Mar―03 Novavax COVID-19 vaccine-related myocarditis/pericarditis
131 [GO] 2023―Mar―03 HPRA safety update on COVID-19 vaccines up to January 2023
132 [GO] 2023―Mar―03 COVID-19-vaccine
133 [GO] 2023―Mar―03 COVID-19-vaccine/rosuvastatin
134 [GO] 2023―Mar―03 COVID-19-vaccines/fondaparinux-sodium/mannitol
135 [GO] 2023―Mar―03 Sars-cov-2-vaccine-inactivated-sinovac-biotech
136 [GO] 2023―Feb―25 More AEFIs reported after COVID-19 vaccination in females than in males
137 [GO] 2023―Feb―25 COVID-19 vaccine
138 [GO] 2023―Feb―25 Covid-19 vaccine/rituximab
139 [GO] 2023―Feb―25 COVID-19-vaccine
140 [GO] 2023―Feb―25 COVID-19-vaccine
141 [GO] 2023―Feb―25 COVID-19-vaccine
142 [GO] 2023―Feb―25 Covid-19-vaccine
143 [GO] 2023―Feb―25 COVID-19-vaccine
144 [GO] 2023―Feb―25 Covid-19-vaccine
145 [GO] 2023―Feb―25 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
146 [GO] 2023―Feb―25 Covid-19-vaccines
147 [GO] 2023―Feb―25 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
148 [GO] 2023―Feb―25 Sars-cov-2-vaccine-inactivated-sinovac-biotech
149 [GO] 2023―Feb―17 Adverse events following COVID-19 vaccination common but mild in haemodialysis patients
150 [GO] 2023―Feb―17 Covid-19-vaccine
151 [GO] 2023―Feb―17 COVID-19-vaccines
152 [GO] 2023―Feb―11 COVID-19 rebound after use of Paxlovid
153 [GO] 2023―Feb―11 Pregnant women have known AEs after COVID-19 vaccination
154 [GO] 2023―Feb―11 COVID-19 vaccine
155 [GO] 2023―Feb―11 COVID-19 vaccine
156 [GO] 2023―Feb―11 COVID-19 vaccine
157 [GO] 2023―Feb―11 COVID-19 vaccine/rituximab
158 [GO] 2023―Feb―11 Covid-19-vaccine
159 [GO] 2023―Feb―11 COVID-19-vaccine/influenza-virus-vaccine
160 [GO] 2023―Feb―11 Covid-19-vaccine/methylprednisolone
161 [GO] 2023―Feb―11 COVID-19-vaccines/prednisone
162 [GO] 2023―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
163 [GO] 2023―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
164 [GO] 2023―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
165 [GO] 2023―Feb―11 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
166 [GO] 2023―Feb―03 COVID-19-vaccine
167 [GO] 2023―Feb―03 SARS-COV-2-vaccine-inactivated-sinovac-biotech
168 [GO] 2023―Jan―30 Safety of co-administered mRNA COVID-19 and influenza vaccines
169 [GO] 2023―Jan―30 Cilgavimab/tixagevimab unlikely to be active against some COVID-19 Omicron subvariants
170 [GO] 2023―Jan―30 COVID-19 vaccine
171 [GO] 2023―Jan―30 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
172 [GO] 2023―Jan―30 COVID-19-vaccine/nirmatrelvir+ritonavir
173 [GO] 2023―Jan―20 Thyroid dysfunction after COVID-19 vaccination
174 [GO] 2023―Jan―20 COVID-19-vaccine
175 [GO] 2023―Jan―20 COVID-19-vaccine
176 [GO] 2023―Jan―20 COVID-19-vaccines/dexamethasone/tocilizumab
177 [GO] 2023―Jan―20 Sars-cov-2-vaccine inactivated sinovac biotech
178 [GO] 2023―Jan―20 Sars-cov-2-vaccine inactivated sinovac biotech
179 [GO] 2023―Jan―15 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
180 [GO] 2023―Jan―15 Covid-19-vaccine
181 [GO] 2023―Jan―15 Covid-19-vaccine/tozinameran
182 [GO] 2023―Jan―15 No new safety signals after COVID-19 vaccination in New Zealand
183 [GO] 2023―Jan―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
184 [GO] 2023―Jan―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
185 [GO] 2023―Jan―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
186 [GO] 2023―Jan―14 COVID-19-vaccines
187 [GO] 2023―Jan―14 Covid-19-vaccine-pfizer-biontech/remdesivir
188 [GO] 2023―Jan―14 Covid-19-vaccine/peginterferon-alfa-2a
189 [GO] 2023―Jan―14 COVID-19-vaccine
190 [GO] 2023―Jan―14 COVID-19-vaccine
191 [GO] 2023―Jan―14 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
192 [GO] 2023―Jan―14 COVID-19-vaccine
193 [GO] 2023―Jan―14 Covid-19-vaccine
194 [GO] 2023―Jan―14 Covid-19-vaccine
195 [GO] 2023―Jan―14 Covid-19-vaccine
196 [GO] 2023―Jan―14 Covid-19-vaccine
197 [GO] 2023―Jan―14 COVID-19 vaccines
198 [GO] 2023―Jan―14 POTS less frequent after COVID-19 vaccine than after COVID infection
199 [GO] 2023―Jan―14 COVID-19 vaccine
200 [GO] 2022―Dec―16 ADRs following use of oral COVID-19 therapeutics (Paxlovid, Lagevrio) in New Zealand
201 [GO] 2022―Dec―16 Covid-19-vaccine
202 [GO] 2022―Dec―16 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
203 [GO] 2022―Dec―16 Sars-cov-2-vaccine-inactivated
204 [GO] 2022―Dec―10 FDA drug safety surveillance during COVID-19 pandemic
205 [GO] 2022―Dec―10 COVID-19 vaccine
206 [GO] 2022―Dec―10 Safety of second Pfizer-BioNTech COVID-19 vaccine booster
207 [GO] 2022―Dec―10 Covid-19-vaccine
208 [GO] 2022―Dec―10 Covid-19-vaccine
209 [GO] 2022―Dec―10 Covid-19-vaccine
210 [GO] 2022―Dec―10 Covid-19-vaccine
211 [GO] 2022―Dec―10 COVID-19-vaccine/nivolumab/pembrolizumab
212 [GO] 2022―Dec―10 Covid-19-vaccine/ocrelizumab
213 [GO] 2022―Dec―10 SARS-COV-2-vaccine-inactivated-sinovac-biotech
214 [GO] 2022―Dec―10 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
215 [GO] 2022―Dec―02 COVID-19 vaccines safe in patients with systemic lupus erythematosus
216 [GO] 2022―Dec―02 COVID-19-vaccine
217 [GO] 2022―Dec―02 Covid-19-vaccine
218 [GO] 2022―Dec―02 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
219 [GO] 2022―Dec―02 Covid-19-vaccine/elasomeran/tozinameran
220 [GO] 2022―Dec―02 COVID-19-vaccines/immunosuppressants/tocilizumab
221 [GO] 2022―Nov―28 Severe AEs after COVID-19 vaccination following COVID-19 infection
222 [GO] 2022―Nov―28 Dedicated system for COVID-19 vaccine safety surveillance at Lareb
223 [GO] 2022―Nov―28 COVID-19 vaccine-associated Guillain-Barre syndrome
224 [GO] 2022―Nov―28 COVID-19-vaccine
225 [GO] 2022―Nov―28 Covid-19-vaccine
226 [GO] 2022―Nov―28 COVID-19-vaccines
227 [GO] 2022―Nov―28 COVID-19-vaccines/prednisone
228 [GO] 2022―Nov―28 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
229 [GO] 2022―Nov―19 COVID-19 vaccine-related neuralgic amyotrophy
230 [GO] 2022―Nov―19 Pfizer-BioNTech and Moderna COVID-19 vaccines safe in Japan
231 [GO] 2022―Nov―19 COVID-19-vaccine
232 [GO] 2022―Nov―19 Covid-19-vaccine
233 [GO] 2022―Nov―19 COVID-19-vaccine/propylthiouracil
234 [GO] 2022―Nov―11 Pfizer-BioNTech COVID-19 vaccination in children: no serious AEs
235 [GO] 2022―Nov―11 Covid-19-vaccine
236 [GO] 2022―Nov―11 Covid-19-vaccine
237 [GO] 2022―Nov―11 COVID-19-vaccine
238 [GO] 2022―Nov―11 Covid-19-vaccine
239 [GO] 2022―Nov―11 Covid-19-vaccine
240 [GO] 2022―Nov―11 COVID-19-vaccines
241 [GO] 2022―Nov―07 Risks of thrombosis and thromboembolic events after first COVID-19 vaccination
242 [GO] 2022―Nov―07 No pregnancy complications after use of mRNA COVID-19 vaccines
243 [GO] 2022―Nov―07 Covid-19-vaccine
244 [GO] 2022―Nov―07 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
245 [GO] 2022―Nov―07 COVID-19-vaccines/immune-globulin/methylprednisolone
246 [GO] 2022―Oct―28 AEs in children after Pfizer-BioNTech COVID-19 vaccine
247 [GO] 2022―Oct―28 Safety of BNT162b2 COVID-19 vaccine comparable to that of other approved vaccines in young children
248 [GO] 2022―Oct―28 Risk of COVID-19 vaccine-related tinnitus
249 [GO] 2022―Oct―28 Covid-19-vaccine
250 [GO] 2022―Oct―28 Covid-19-vaccine
251 [GO] 2022―Oct―28 COVID-19-vaccine/immune-globulin/methylprednisolone
252 [GO] 2022―Oct―28 Sars-cov-2-vaccine-inactivated-sinovac-biotech
253 [GO] 2022―Oct―28 Sars-cov-2-vaccine-inactivated-sinovac-biotech
254 [GO] 2022―Oct―21 Multiple sclerosis immunotherapies increase risk of COVID-19 mortality
255 [GO] 2022―Oct―21 AEs after COVID-19 vaccination in patients with epilepsy
256 [GO] 2022―Oct―21 COVID-19 vaccine-related anaphylaxis and other allergic reactions
257 [GO] 2022―Oct―21 COVID-19-vaccine
258 [GO] 2022―Oct―21 Covid-19-vaccine
259 [GO] 2022―Oct―21 Covid-19-vaccine
260 [GO] 2022―Oct―21 Covid-19-vaccine
261 [GO] 2022―Oct―21 Covid-19-vaccine
262 [GO] 2022―Oct―21 Covid-19-vaccine
263 [GO] 2022―Oct―21 COVID-19-vaccine-pfizer-biontech/lisinopril/metoprolol
264 [GO] 2022―Oct―21 COVID-19-vaccine/temozolomide
265 [GO] 2022―Oct―21 COVID-19-vaccines
266 [GO] 2022―Oct―21 COVID-19-vaccines
267 [GO] 2022―Oct―14 mRNA COVID-19 vaccine safety in recipients aged 12 to 64 years
268 [GO] 2022―Oct―14 Covid-19-vaccine
269 [GO] 2022―Oct―14 COVID-19-vaccine
270 [GO] 2022―Oct―14 Covid-19-vaccine/elasomeran/tozinameran
271 [GO] 2022―Oct―14 Covid-19-vaccine/olanzapine
272 [GO] 2022―Oct―14 SARS-COV-2 vaccine inactivated Sinovac Biotech
273 [GO] 2022―Oct―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
274 [GO] 2022―Oct―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
275 [GO] 2022―Oct―07 COVID-19 vaccination may trigger tattoo skin reactions
276 [GO] 2022―Oct―07 Coronavirus-vaccine
277 [GO] 2022―Oct―07 Coronavirus-vaccine-stemirna-therapeutics/tongji-university/tozinameran
278 [GO] 2022―Oct―07 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
279 [GO] 2022―Oct―01 Headache common after COVID-19 vaccination
280 [GO] 2022―Oct―01 COVID-19 vaccine
281 [GO] 2022―Oct―01 Sars-cov-2-vaccine-inactivated-sinovac-biotech
282 [GO] 2022―Sep―23 Myocardial injury after 4th dose of Pfizer-BioNTech COVID-19 vaccine
283 [GO] 2022―Sep―23 Novavax COVID-19 vaccine-related myocarditis and pericarditis
284 [GO] 2022―Sep―23 Side effects common after first dose of COVID-19 vaccine: a survey from Spain
285 [GO] 2022―Sep―23 COVID-19-vaccine
286 [GO] 2022―Sep―23 COVID-19-vaccine
287 [GO] 2022―Sep―23 Covid-19-vaccine
288 [GO] 2022―Sep―23 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
289 [GO] 2022―Sep―23 Covid-19-vaccine/methotrexate/tumour-necrosis-factor-inhibitors
290 [GO] 2022―Sep―23 COVID-19-vaccines/prednisolone/rituximab
291 [GO] 2022―Sep―16 COVID-19 outcome not worsened by remdesivir-induced bradycardia
292 [GO] 2022―Sep―16 Serious AEs of special interest after mRNA COVID-19 vaccination
293 [GO] 2022―Sep―16 COVID-19 vaccine
294 [GO] 2022―Sep―16 Sars-cov-2-vaccine-inactivated-sinovac-biotech
295 [GO] 2022―Sep―16 Sars-cov-2-vaccine-inactivated-sinovac-biotech
296 [GO] 2022―Sep―09 TTS rare after AstraZeneca COVID-19 vaccine
297 [GO] 2022―Sep―09 Safety profile of BBV152 COVID-19 vaccine favourable in adolescents in India
298 [GO] 2022―Sep―09 Covid-19-vaccine
299 [GO] 2022―Sep―09 Covid-19-vaccine/elasomeran
300 [GO] 2022―Sep―02 COVID-19 vaccination safe during pregnancy
301 [GO] 2022―Sep―02 COVID-19 vaccine
302 [GO] 2022―Sep―02 AstraZeneca, Pfizer-BioNTech, Sinopharm, Sputnik V COVID-19 vaccine
303 [GO] 2022―Sep―02 Covid-19 vaccine Gamaleya national research center of epidemiology and microbiology/fenoterol/ipratropium bromide
304 [GO] 2022―Sep―02 Adenoviral-based COVID-19 vaccines may increase risk of MI and PE
305 [GO] 2022―Sep―02 COVID-19-vaccine
306 [GO] 2022―Sep―02 COVID-19-vaccine
307 [GO] 2022―Sep―02 COVID-19-Vaccine-Pfizer-BioNTech
308 [GO] 2022―Sep―02 SARS-COV-2 vaccine-inactivated Sinovac-Biotech
309 [GO] 2022―Sep―02 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
310 [GO] 2022―Aug―26 COVID-19 mRNA vaccines safe in pregnancy
311 [GO] 2022―Aug―26 COVID-19 vaccination hesitancy may drive AE reporting
312 [GO] 2022―Aug―26 Novavax COVID-19 vaccine-related myocarditis, pericarditis
313 [GO] 2022―Aug―26 Covid-19-vaccine
314 [GO] 2022―Aug―26 COVID-19-vaccine/dexamethasone/tobramycin
315 [GO] 2022―Aug―19 Cutaneous reactions after COVID-19 vaccination
316 [GO] 2022―Aug―19 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
317 [GO] 2022―Aug―19 COVID-19-vaccines/immune globulin
318 [GO] 2022―Aug―12 Serious AEs uncommon after second mRNA COVID-19 booster
319 [GO] 2022―Aug―12 AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia case fatalities
320 [GO] 2022―Aug―12 COVID-19 vaccines: risk of oral adverse events
321 [GO] 2022―Aug―12 Covid-19-vaccine
322 [GO] 2022―Aug―12 Sars-cov-2-vaccine-inactivated-sinovac-biotech
323 [GO] 2022―Aug―12 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
324 [GO] 2022―Aug―06 Covid-19 vaccine
325 [GO] 2022―Aug―06 COVID-19-vaccine
326 [GO] 2022―Jul―29 Safety of COVID-19 mRNA vaccine first booster doses among immunocompromised persons
327 [GO] 2022―Jul―29 COVID-19 vaccination: reports of Bell's palsy
328 [GO] 2022―Jul―29 COVID-19 vaccine
329 [GO] 2022―Jul―29 COVID-19 vaccine: risk of increased menstrual bleeding
330 [GO] 2022―Jul―29 COVID-19-vaccine
331 [GO] 2022―Jul―29 COVID-19-vaccine/ipilimumab/nivolumab
332 [GO] 2022―Jul―29 COVID-19-vaccines
333 [GO] 2022―Jul―23 Covid-19-vaccine
334 [GO] 2022―Jul―23 COVID-19-vaccine
335 [GO] 2022―Jul―23 Sars-cov-2 vaccine inactivated Sinovac Biotech/tozinameran
336 [GO] 2022―Jul―15 Covid-19 vaccine
337 [GO] 2022―Jul―15 Active surveillance confirms short-term safety of COVID-19 vaccines in Australia
338 [GO] 2022―Jul―15 COVID-19 vaccines: reports of lichen planus
339 [GO] 2022―Jul―15 Covid-19-vaccine
340 [GO] 2022―Jul―15 Covid-19-vaccine
341 [GO] 2022―Jul―15 Covid-19-vaccine
342 [GO] 2022―Jul―15 COVID-19-vaccine
343 [GO] 2022―Jul―15 Covid-19-vaccine-pfizer-biontech/elasomeran
344 [GO] 2022―Jul―15 Sars-cov-2-vaccine-inactivated-sinovac-biotech
345 [GO] 2022―Jul―08 Myocarditis/pericarditis rare after COVID-19 mRNA vaccination
346 [GO] 2022―Jul―08 Covid-19 vaccine pfizer biontech
347 [GO] 2022―Jul―08 Covid-19 vaccine pfizer biontech
348 [GO] 2022―Jul―08 Covid-19-vaccine
349 [GO] 2022―Jul―08 Covid-19-vaccine
350 [GO] 2022―Jul―08 COVID-19-vaccine
351 [GO] 2022―Jul―08 SARS-COV-2-vaccine inactivated Sinovac Biotech
352 [GO] 2022―Jul―08 Sars-cov-2-vaccine-inactivated-sinovac-biotech
353 [GO] 2022―Jul―08 Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran
354 [GO] 2022―Jul―01 Covid-19 vaccine
355 [GO] 2022―Jul―01 COVID-19 vaccine Pfizer BioNTech
356 [GO] 2022―Jul―01 Signal detection of COVID-19 vaccine-related AEs
357 [GO] 2022―Jul―01 COVID-19-vaccine
358 [GO] 2022―Jul―01 COVID-19-Vaccine-Pfizer-BioNTech
359 [GO] 2022―Jul―01 Covid-19-vaccine-Pfizer-BioNTech
360 [GO] 2022―Jul―01 Covid-19-vaccine-pfizer-biontech
361 [GO] 2022―Jul―01 Covid-19-vaccine-pfizer-biontech
362 [GO] 2022―Jul―01 Covid-19-vaccine-pfizer-biontech
363 [GO] 2022―Jul―01 COVID-19-vaccine-Pfizer-Biontech/elasomeran
364 [GO] 2022―Jul―01 Covid-19-vaccine-pfizer-biontech/olanzapine/tetrabenazine
365 [GO] 2022―Jul―01 COVID-19-vaccines/immunosuppressants
366 [GO] 2022―Jul―01 SARS-CoV-2 vaccine inactivated Sinovac Biotech
367 [GO] 2022―Jul―01 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
368 [GO] 2022―Jun―23 Acute neurological AEs after COVID-19 vaccination
369 [GO] 2022―Jun―23 COVID-19 vaccination and risk of neuralgic amyotrophy
370 [GO] 2022―Jun―23 COVID-19 vaccination relatively safe in autoimmune diseases
371 [GO] 2022―Jun―23 COVID-19 vaccines/mycophenolate mofetil
372 [GO] 2022―Jun―23 Sars-cov-2-vaccine-inactivated
373 [GO] 2022―Jun―23 Sars-cov-2-vaccine-inactivated-sinovac-biotech
374 [GO] 2022―Jun―23 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
375 [GO] 2022―Jun―23 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
376 [GO] 2022―Jun―17 Risk of myocarditis or pericarditis after COVID-19 mRNA vaccines
377 [GO] 2022―Jun―17 Risk of Guillain-Barre Syndrome after COVID-19 vaccination
378 [GO] 2022―Jun―17 Janssen COVID-19 vaccine increases risk of thrombocytopenia
379 [GO] 2022―Jun―17 COVID-19 vaccine-Pfizer-BioNTech
380 [GO] 2022―Jun―17 Covid-19-vaccine first report
381 [GO] 2022―Jun―17 Covid-19-vaccine-pfizer-biontech
382 [GO] 2022―Jun―17 SARS-COV-2-vaccine-inactivated Sinovac-Biotech
383 [GO] 2022―Jun―17 Sars-cov-2-vaccine-inactivated-sinovac-biotech
384 [GO] 2022―Jun―17 Sars-cov-2-vaccine-inactivated-sinovac-biotech
385 [GO] 2022―Jun―10 AEs after homologous versus heterologous COVID-19 booster
386 [GO] 2022―Jun―10 Standardised assessment of COVID-19 vaccine-related skin reactions
387 [GO] 2022―Jun―10 Safety of mRNA COVID-19 vaccines during pregnancy
388 [GO] 2022―Jun―10 Covid-19-vaccine/lamotrigine
389 [GO] 2022―Jun―03 Low risk of myopericarditis after COVID-19 vaccination in children aged 5-11 years
390 [GO] 2022―Jun―03 Pfizer-BioNTech COVID-19 vaccine safe with clozapine
391 [GO] 2022―Jun―03 COVID-19 vaccine-induced VITT/TSS in Malaysia
392 [GO] 2022―Jun―03 Lareb study on COVID-19 vaccine-related menstrual disorders
393 [GO] 2022―Jun―03 COVID-19-vaccine
394 [GO] 2022―Jun―03 COVID-19-vaccine
395 [GO] 2022―Jun―03 COVID-19-Vaccine-Pfizer-BioNTech
396 [GO] 2022―Jun―03 Covid-19-vaccine-pfizer-biontech
397 [GO] 2022―Jun―03 COVID-19-vaccine-Pfizer-BioNtech
398 [GO] 2022―Jun―03 COVID-19-vaccine/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
399 [GO] 2022―Jun―03 Sars-cov-2-vaccine-inactivated-sinovac-biotech
400 [GO] 2022―Jun―03 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
401 [GO] 2022―Jun―03 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
402 [GO] 2022―May―27 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
403 [GO] 2022―May―27 Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
404 [GO] 2022―May―27 Pfizer-BioNTech COVID-19 vaccine safe in children
405 [GO] 2022―May―27 Covid-19-vaccine
406 [GO] 2022―May―27 Covid-19-vaccine
407 [GO] 2022―May―27 Covid-19-vaccine
408 [GO] 2022―May―27 Covid-19-vaccine-pfizer-biontech
409 [GO] 2022―May―27 Covid-19-vaccine-pfizer-biontech/elasomeran
410 [GO] 2022―May―20 ADRs due to off-label use of hydroxychloroquine for COVID-19
411 [GO] 2022―May―20 Survey of adverse events following ChAdOx1 COVID-19 vaccination in Ethiopia
412 [GO] 2022―May―20 COVID-19-vaccine
413 [GO] 2022―May―20 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/immunosuppressants
414 [GO] 2022―May―20 COVID-19-Vaccine-Pfizer-BioNTech
415 [GO] 2022―May―20 Covid-19-vaccine-pfizer-biontech
416 [GO] 2022―May―20 Covid-19-vaccine-pfizer-biontech/levothyroxine-sodium/sars-cov-2-vaccine-inactivated-sinovac-biotech
417 [GO] 2022―May―20 COVID-19-vaccines/budesonide/mesalazine
418 [GO] 2022―May―13 FDA limits authorised use of Janssen COVID-19 vaccine
419 [GO] 2022―May―13 Covid-19-vaccine-pfizer-biontech
420 [GO] 2022―May―13 COVID-19-Vaccine-Pfizer-BioNTech
421 [GO] 2022―May―13 Covid-19-vaccine-pfizer-biontech
422 [GO] 2022―May―13 COVID-19-vaccine/plasma
423 [GO] 2022―May―13 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
424 [GO] 2022―May―06 COVID-19 vaccination may reactivate varicella-zoster virus
425 [GO] 2022―May―06 COVID-19-Vaccine-Pfizer-BioNTech
426 [GO] 2022―May―06 COVID-19-Vaccine-Pfizer-BioNTech
427 [GO] 2022―Apr―29 No increased risk for venous thromboembolism after COVID-19 vaccination
428 [GO] 2022―Apr―29 Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed
429 [GO] 2022―Apr―29 COVID-19 vaccine Gamaleya National Research Center of Epidemiology and Microbiology
430 [GO] 2022―Apr―29 COVID-19 Vaccine Pfizer BioNTech
431 [GO] 2022―Apr―29 Covid-19-vaccine
432 [GO] 2022―Apr―29 COVID-19-Vaccine-Pfizer-BioNTech/pegfilgrastim/pembrolizumab
433 [GO] 2022―Apr―29 Covid-19-vaccine/methylprednisolone
434 [GO] 2022―Apr―29 COVID-19-vaccine/mycophenolate
435 [GO] 2022―Apr―22 Cardiac risks higher after COVID-19 infection than mRNA vaccine
436 [GO] 2022―Apr―22 Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
437 [GO] 2022―Apr―22 PRAC meeting highlights April 2022: no link between mRNA COVID-19 vaccines and autoimmune hepatitis
438 [GO] 2022―Apr―22 Covid-19-vaccine
439 [GO] 2022―Apr―22 Covid-19-vaccine-pfizer-biontech
440 [GO] 2022―Apr―22 COVID-19-Vaccine-Pfizer-BioNTech
441 [GO] 2022―Apr―22 COVID-19-Vaccine-Pfizer-BioNTech/elasomeran
442 [GO] 2022―Apr―22 Covid-19-vaccine-pfizer-biontech/prednisone/valaciclovir
443 [GO] 2022―Apr―22 COVID-19-vaccines/immune-globulin/methylprednisolone
444 [GO] 2022―Apr―22 Coronavirus-vaccine
445 [GO] 2022―Apr―14 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
446 [GO] 2022―Apr―14 Covid-19-vaccine-pfizer-biontech
447 [GO] 2022―Apr―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
448 [GO] 2022―Apr―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
449 [GO] 2022―Apr―08 Remdesivir does not increase risk of AKI or ALI in COVID-19 patients
450 [GO] 2022―Apr―08 COVID-19 vaccine-Pfizer-BioNTech/methylprednisolone aceponate
451 [GO] 2022―Apr―08 No evidence of adverse neurological outcomes from COVID-19 vaccines
452 [GO] 2022―Apr―08 Covid-19-vaccine
453 [GO] 2022―Apr―08 COVID-19-vaccine
454 [GO] 2022―Apr―08 Covid-19-vaccine
455 [GO] 2022―Apr―08 Covid-19-vaccine-pfizer-biontech
456 [GO] 2022―Apr―08 Covid-19-vaccine-pfizer-biontech
457 [GO] 2022―Apr―08 COVID-19-Vaccine-Pfizer-BioNTech
458 [GO] 2022―Apr―08 COVID-19-Vaccine-Pfizer-BioNTech
459 [GO] 2022―Apr―08 Covid-19-vaccine/evolocumab
460 [GO] 2022―Apr―08 Sars-cov-2-vaccine-inactivated-sinovac-biotech
461 [GO] 2022―Apr―08 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
462 [GO] 2022―Apr―01 No safety signal after COVID-19 vaccination for immune-mediated neurological events
463 [GO] 2022―Apr―01 Myocarditis after third dose of Pfizer-BioNTech COVID-19 vaccine
464 [GO] 2022―Apr―01 COVID-19-vaccine
465 [GO] 2022―Apr―01 Covid-19-vaccine
466 [GO] 2022―Apr―01 COVID-19-Vaccine-Pfizer-BioNTech
467 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech
468 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech
469 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech/ibuprofen/paracetamol/meloxicam
470 [GO] 2022―Apr―01 Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
471 [GO] 2022―Mar―25 Systemic AEs common after COVID-19 vaccination
472 [GO] 2022―Mar―25 COVID-19 vaccine Gamaleya National Research Center of Epidermiology and Microbiology
473 [GO] 2022―Mar―25 Covid-19 vaccine-Pfizer-BioNtech
474 [GO] 2022―Mar―25 Covid-19-vaccine
475 [GO] 2022―Mar―25 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/fexofenadine
476 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech
477 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech
478 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech/sars-cov-2-vaccine-inactivated-sinovac-biotech
479 [GO] 2022―Mar―25 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
480 [GO] 2022―Mar―19 Covid-19-vaccine-pfizer-biontech
481 [GO] 2022―Mar―19 COVID-19-Vaccine-Pfizer-BioNTech/elasomeran
482 [GO] 2022―Mar―19 Sars-cov-2-vaccine-inactivated-sinovac-biotech
483 [GO] 2022―Mar―19 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
484 [GO] 2022―Mar―19 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
485 [GO] 2022―Mar―11 Covid-19-vaccine-pfizer-biontech
486 [GO] 2022―Mar―11 Covid-19-vaccine-pfizer-biontech/elasomeran
487 [GO] 2022―Mar―11 Coronavirus-vaccine
488 [GO] 2022―Mar―11 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
489 [GO] 2022―Mar―05 Health Canada: risk of accidental poisoning from COVID-19 rapid antigen test kits
490 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
491 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
492 [GO] 2022―Mar―05 COVID-19-vaccine-pfizer-biontech
493 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
494 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
495 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech
496 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
497 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech
498 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech/omalizumab
499 [GO] 2022―Mar―05 Covid-19-vaccine/vildagliptin interaction
500 [GO] 2022―Mar―05 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
501 [GO] 2022―Feb―25 COVID-19 vaccine
502 [GO] 2022―Feb―25 COVID-19 vaccine
503 [GO] 2022―Feb―25 COVID-19 vaccine
504 [GO] 2022―Feb―25 Covid-19-vaccine
505 [GO] 2022―Feb―25 Covid-19-vaccine-pfizer-biontech
506 [GO] 2022―Feb―25 Covid-19-vaccine-pfizer-biontech
507 [GO] 2022―Feb―25 COVID-19-Vaccine-Pfizer-BioNTech/epinephrine
508 [GO] 2022―Feb―18 Increase in thromboembolic ADRs from oral contraceptives during COVID-19 pandemic in Spain
509 [GO] 2022―Feb―18 No adverse effects found for prenatal exposure to mRNA COVID-19 vaccine
510 [GO] 2022―Feb―18 COVID-19 Vaccine Pfizer BioNTech
511 [GO] 2022―Feb―18 COVID-19 Vaccine Pfizer BioNTech
512 [GO] 2022―Feb―18 COVID-19-Vaccine-Pfizer-BioNTech
513 [GO] 2022―Feb―18 COVID-19-Vaccine-Pfizer-BioNTech
514 [GO] 2022―Feb―18 Coronavirus-vaccine
515 [GO] 2022―Feb―18 Sars-cov-2-vaccine-inactivated-sinovac-biotech
516 [GO] 2022―Feb―11 mRNA COVID-19 vaccines safe in patients with previous COVID-19 infections
517 [GO] 2022―Feb―11 COVID-19 vaccine errors dominate ISMP's list of top 10 safety concerns for 2021
518 [GO] 2022―Feb―11 Covid-19-vaccine-pfizer-biontech
519 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
520 [GO] 2022―Feb―11 Covid-19-vaccine-pfizer-biontech
521 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
522 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
523 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
524 [GO] 2022―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
525 [GO] 2022―Feb―04 Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination
526 [GO] 2022―Feb―04 COVID-19 vaccine
527 [GO] 2022―Feb―04 Growing evidence reassuring for mRNA COVID-19 vaccines in pregnancy
528 [GO] 2022―Feb―04 COVID-19-vaccine
529 [GO] 2022―Feb―04 Covid-19-vaccine
530 [GO] 2022―Feb―04 Covid-19-vaccine
531 [GO] 2022―Jan―28 Reported rates of CVST due to COVID-19 vaccination rose after publicising these ADRs
532 [GO] 2022―Jan―28 Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event
533 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
534 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
535 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
536 [GO] 2022―Jan―28 COVID-19-Vaccine-Pfizer-BioNTech
537 [GO] 2022―Jan―28 COVID-19-Vaccine-Pfizer-BioNTech
538 [GO] 2022―Jan―28 Coronavirus-vaccine
539 [GO] 2022―Jan―28 Coronavirus-vaccine
540 [GO] 2022―Jan―21 COVID-19 vaccines safe in people living with HIV
541 [GO] 2022―Jan―21 SARS-COV-2 vaccine inactivated Sinovac Biotech
542 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
543 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
544 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
545 [GO] 2022―Jan―14 Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
546 [GO] 2022―Jan―14 Rare reports of rheumatic disorder flares after COVID-19 vaccination
547 [GO] 2022―Jan―14 Small change in menstrual cycle length after COVID-19 vaccination
548 [GO] 2022―Jan―14 Expected rates of adverse events after COVID-19 vaccination in USA
549 [GO] 2022―Jan―14 Covid-19-vaccine/tozinameran
550 [GO] 2022―Jan―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
551 [GO] 2022―Jan―06 Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines
552 [GO] 2022―Jan―06 COVID-19 Vaccine Pfizer BioNTech
553 [GO] 2022―Jan―06 Signal for COVID-19 vaccine-related menstrual disorders
554 [GO] 2022―Jan―06 Systematic review: COVID-19 vaccine-related neurological disorders "exceedingly" rare
555 [GO] 2022―Jan―06 COVID-19-vaccine
556 [GO] 2022―Jan―06 COVID-19-vaccine
557 [GO] 2022―Jan―06 COVID-19-vaccine
558 [GO] 2022―Jan―06 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
559 [GO] 2022―Jan―06 COVID-19-Vaccine-Pfizer-BioNTech
560 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
561 [GO] 2022―Jan―06 COVID-19-Vaccine-Pfizer-BioNTech
562 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
563 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
564 [GO] 2022―Jan―06 Covid-19-vaccine/influenza-virus-vaccine
565 [GO] 2022―Jan―06 Covid-19-vaccine/mrna-1273
566 [GO] 2022―Jan―06 SARS-COV-2 vaccine inactivated-Sinovac-Biotech
567 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
568 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
569 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
570 [GO] 2021―Dec―18 COVID-19 Vaccine Pfizer-BioNTech
571 [GO] 2021―Dec―18 Most adolescent myocarditis cases related to covid-19 vaccines mild, resolve quickly
572 [GO] 2021―Dec―18 Covid-19-vaccine-pfizer-biontech
573 [GO] 2021―Dec―18 COVID-19-Vaccine-Pfizer-BioNTech
574 [GO] 2021―Dec―18 Coronavirus vaccine
575 [GO] 2021―Dec―18 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
576 [GO] 2021―Dec―18 Sars-cov-2-vaccine-inactivated-sinovac-biotech
577 [GO] 2021―Dec―10 Safety of seven COVID-19 vaccine booster doses
578 [GO] 2021―Dec―10 Myocarditis, pericarditis with COVID-19 vaccines in the Netherlands
579 [GO] 2021―Dec―10 COVID-19 vaccines/rituximab
580 [GO] 2021―Dec―10 COVID-19-Vaccine-Pfizer-BioNTech
581 [GO] 2021―Dec―10 COVID-19-Vaccine-Pfizer-BioNTech
582 [GO] 2021―Dec―10 Covid-19-vaccine/immune-globulin/methylprednisolone
583 [GO] 2021―Dec―10 COVID-19-vaccines
584 [GO] 2021―Dec―10 Covid-19-vaccines/rituximab
585 [GO] 2021―Dec―10 Sars-cov-2-vaccine-inactivated-sinovac-biotech
586 [GO] 2021―Dec―10 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
587 [GO] 2021―Dec―04 Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
588 [GO] 2021―Dec―04 No increase in stroke, MI or PE after Pfizer-BioNTech COVID-19 vaccine
589 [GO] 2021―Dec―04 Adverse reactions with Pfizer/BioNTech's COVID-19 vaccine in Ecuador
590 [GO] 2021―Dec―04 Pfizer-BioNTech COVID-19 vaccine safe in older Koreans
591 [GO] 2021―Dec―04 COVID-19-vaccine
592 [GO] 2021―Dec―04 COVID-19-Vaccine-Pfizer-BioNTech
593 [GO] 2021―Dec―04 Covid-19-vaccine-pfizer-biontech
594 [GO] 2021―Dec―04 Covid-19-vaccine-pfizer-biontech
595 [GO] 2021―Dec―04 COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273
596 [GO] 2021―Dec―04 Coronavirus-vaccine
597 [GO] 2021―Dec―04 Coronavirus-vaccine-Wuhan-Institute-of-Biological-Products
598 [GO] 2021―Nov―26 Cutaneous vasculitis following COVID-19 vaccination
599 [GO] 2021―Nov―26 COVID-19 vaccine Pfizer BioNTech
600 [GO] 2021―Nov―26 Possibility of mix-up with paediatric COVID-19 vaccines
601 [GO] 2021―Nov―26 COVID-19-Vaccine-Pfizer-BioNTech
602 [GO] 2021―Nov―26 Covid-19-vaccine-pfizer-biontech
603 [GO] 2021―Nov―26 Covid-19-vaccine-pfizer-biontech
604 [GO] 2021―Nov―19 Myocarditis rare after COVID-19 mRNA vaccination
605 [GO] 2021―Nov―19 Increased risk of immune thrombocytopenia following AstraZeneca Covid-19 vaccine
606 [GO] 2021―Nov―19 English-only labels for Janssen's COVID-19 vaccine in Canada
607 [GO] 2021―Nov―19 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
608 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
609 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
610 [GO] 2021―Nov―19 COVID-19-Vaccine-Pfizer-BioNTech
611 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
612 [GO] 2021―Nov―19 COVID-19-vaccine-pfizer-biontech/ibuprofen/oxycodone
613 [GO] 2021―Nov―19 Covid-19-vaccine-Pfizer-BioNTech/mRNA-1273
614 [GO] 2021―Nov―05 COVID-19 vaccine
615 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
616 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
617 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
618 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
619 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
620 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
621 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273
622 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech/mycophenolic acid/tacrolimus
623 [GO] 2021―Nov―05 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
624 [GO] 2021―Oct―29 Covid-19-vaccine-pfizer-biontech
625 [GO] 2021―Oct―29 COVID-19-Vaccine-Pfizer-BioNTech
626 [GO] 2021―Oct―29 Covid-19-vaccine/rituximab
627 [GO] 2021―Oct―22 COVID-19-Vaccine-Pfizer-BioNTech
628 [GO] 2021―Oct―22 Covid-19-vaccine-pfizer-biontech
629 [GO] 2021―Oct―22 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
630 [GO] 2021―Oct―16 Pfizer-BioNTech COVID-19 vaccine in patients with severe allergies
631 [GO] 2021―Oct―16 Covid-19-vaccine
632 [GO] 2021―Oct―16 COVID-19-vaccine
633 [GO] 2021―Oct―16 COVID-19-Vaccine-Pfizer-BioNTech
634 [GO] 2021―Oct―16 SARS-COV-2 vaccine inactivated Sinovac Biotech
635 [GO] 2021―Oct―16 No evidence of birth defects or spontaneous abortion from pandemic H1N1-influenza vaccine
636 [GO] 2021―Oct―10 Covid-19 vaccine-Pfizer-Biontech
637 [GO] 2021―Oct―10 No association between COVID-19 vaccination and menstrual disorders
638 [GO] 2021―Oct―01 FAPIC score predicts mortality after COVID-19 vaccine-related TTS
639 [GO] 2021―Oct―01 Product monographs for COVID-19 vaccines updated in Canada
640 [GO] 2021―Oct―01 Covid-19-vaccine-pfizer-biontech
641 [GO] 2021―Oct―01 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
642 [GO] 2021―Sep―24 COVID-19 vaccination safe during pregnancy
643 [GO] 2021―Sep―24 Covid-19-vaccine-pfizer-biontech
644 [GO] 2021―Sep―17 Minimal risk of GBS relapse after Pfizer-BioNTech COVID-19 vaccination
645 [GO] 2021―Sep―17 COVID-19-Vaccine-Pfizer-BioNTech
646 [GO] 2021―Sep―17 COVID-19-Vaccine-Pfizer-BioNTech/ciclosporin/mycophenolate sodium
647 [GO] 2021―Sep―17 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
648 [GO] 2021―Sep―12 Warnings of risks associated with ivermectin use for COVID-19
649 [GO] 2021―Sep―12 mRNA-based vs viral vector-based COVID-19 vaccines
650 [GO] 2021―Sep―12 Covid-19-vaccine-pfizer-biontech
651 [GO] 2021―Sep―12 COVID-19-Vaccine-Pfizer-BioNTech
652 [GO] 2021―Sep―12 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
653 [GO] 2021―Sep―12 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
654 [GO] 2021―Sep―04 Antihypertensives: sex differences in risk of COVID-19
655 [GO] 2021―Sep―04 Thrombocytopenia and thromboembolism after COVID-19 vaccination
656 [GO] 2021―Sep―04 COVID-19 Vaccine Pfizer BioNTech
657 [GO] 2021―Sep―04 AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
658 [GO] 2021―Sep―04 Covid-19-vaccine-Pfizer-BioNTech
659 [GO] 2021―Sep―04 Covid-19-vaccine-pfizer-biontech
660 [GO] 2021―Sep―04 Covid-19-vaccine-pfizer-biontech
661 [GO] 2021―Sep―04 Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab
662 [GO] 2021―Aug―27 Covid-19 vaccine pfizer biontech
663 [GO] 2021―Aug―27 Teen COVE study finds Moderna COVID-19 vaccine safe in adolescents
664 [GO] 2021―Aug―27 Janssen COVID-19 vaccine-related tinnitus and dizziness
665 [GO] 2021―Aug―27 Covid-19-vaccine-Pfizer-BioNTech
666 [GO] 2021―Aug―21 COVID-19 vaccination encouraged by the EMA/ECDC
667 [GO] 2021―Aug―21 Pfizer-BioNTech COVID-19 vaccine label update on Bell's palsy in Canada
668 [GO] 2021―Aug―21 Cerebral vein thrombosis after four COVID-19 vaccines in Europe
669 [GO] 2021―Aug―21 Covid-19-vaccine-pfizer-biontech
670 [GO] 2021―Aug―21 Covid-19-vaccine-Pfizer-BioNTech/prednisone
671 [GO] 2021―Aug―21 Remdesivir vs tocilizumab in COVID-19: adverse event profiles
672 [GO] 2021―Aug―13 NSAIDs do not increase risk or severity of COVID-19 infections
673 [GO] 2021―Aug―13 Cerebral venous sinus thrombosis after COVID-19 vaccination
674 [GO] 2021―Aug―13 Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan
675 [GO] 2021―Aug―13 PRAC meeting 5 August 2021: COVID-19 vaccine safety issues
676 [GO] 2021―Aug―13 COVID-19-Vaccine-Pfizer-BioNTech
677 [GO] 2021―Aug―13 Covid-19-vaccine-pfizer-biontech
678 [GO] 2021―Aug―13 Covid-19-Vaccine-Pfizer-Biontech
679 [GO] 2021―Aug―13 Covid-19-vaccine-pfizer-biontech/levofloxacin
680 [GO] 2021―Aug―09 WHO GACVS reviews cases of GBS after COVID-19 vaccination
681 [GO] 2021―Aug―09 Rolling review of COVID-19 vaccine Vidprevtyn by EMA
682 [GO] 2021―Aug―09 Revisions of precautions for COVID-19 vaccines and other drugs in Japan
683 [GO] 2021―Aug―09 COVID-19-Vaccine-Pfizer-BioNTech
684 [GO] 2021―Aug―09 Covid-19-vaccine-pfizer-biontech
685 [GO] 2021―Aug―01 EMA assessing safety of anakinra in adults with COVID-19
686 [GO] 2021―Aug―01 PMDA: precautions should be revised for Covid-19 vaccine
687 [GO] 2021―Jul―23 Warning for Janssen COVID-19 vaccine: risk of Guillain-Barré syndrome
688 [GO] 2021―Jul―23 PRAC meeting highlights July 2021: Zynteglo and COVID-19 vaccines
689 [GO] 2021―Jul―23 COVID-19-Vaccine-Pfizer-BioNTech
690 [GO] 2021―Jul―23 Covid-19-vaccine-pfizer-biontech
691 [GO] 2021―Jul―17 AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome
692 [GO] 2021―Jul―05 Myocarditis or pericarditis following COVID-19 vaccination
693 [GO] 2021―Jul―05 Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
694 [GO] 2021―Jul―05 COVID-19-vaccine-pfizer-biontech
695 [GO] 2021―Jul―05 Covid-19-vaccines
696 [GO] 2021―Jun―26 FDA reports recall of Innova COVID-19 antigen rapid qualitative test
697 [GO] 2021―Jun―26 Myocarditis and pericarditis after COVID-19 vaccination
698 [GO] 2021―Jun―26 PRAC June 2021 meeting highlights: COVID-19 vaccine AEs
699 [GO] 2021―Jun―26 US-labelled supply of Moderna's COVID-19 vaccine in Cananda
700 [GO] 2021―Jun―18 Biological or targeted synthetic DMARDs increase COVID-19 severity
701 [GO] 2021―Jun―18 Pfizer-BioNtech's COVID-19 vaccine approved for younger adolescents
702 [GO] 2021―Jun―18 Safeguarding against use of contaminated COVID-19 Vaccine Janssen
703 [GO] 2021―Jun―18 Heterogeneity in potential COVID-19 vaccine-related AEs
704 [GO] 2021―Jun―18 EMA advice on COVID-19 vaccine-related thrombosis with thrombocytopenia
705 [GO] 2021―Jun―12 Nursing home resident deaths after Pfizer-BioNTech's COVID-19 vaccine
706 [GO] 2021―Jun―12 Many Danes with fever after COVID-19 vaccine would contact doctor
707 [GO] 2021―Jun―05 Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines
708 [GO] 2021―Jun―05 Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
709 [GO] 2021―Jun―05 COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab
710 [GO] 2021―May―28 Bleeding and clotting with AstraZeneca's COVID-19 vaccine
711 [GO] 2021―May―28 Updated advice on thrombosis with thrombocytopenia syndrome and use of COVID-19 Vaccine AstraZeneca
712 [GO] 2021―May―21 COVID-19 vaccination during pregnancy: no increase in placental lesions
713 [GO] 2021―May―21 PRAC May 2021 meeting highlights: COVID-19 vaccine AEs
714 [GO] 2021―May―21 Do NSAIDs increase the severity of COVID-19?
715 [GO] 2021―May―14 COVID-19 vaccination errors in USA reported to ISMP
716 [GO] 2021―May―14 TTS with Janssen's COVID-19 vaccine
717 [GO] 2021―May―14 Anxiety disorders with Janssen's COVID-19 vaccine
718 [GO] 2021―May―14 AstraZeneca COVID-19 vaccine-related thromboembolism
719 [GO] 2021―May―14 AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea
720 [GO] 2021―May―07 No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine
721 [GO] 2021―May―07 FDA and CDC recommend resuming use of Janssen COVID-19 vaccine
722 [GO] 2021―May―07 COVID-19 vaccine adverse events reported via app
723 [GO] 2021―May―07 AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia
724 [GO] 2021―May―07 New EMA/ECDC initiative for monitoring COVID-19 vaccines
725 [GO] 2021―May―03 PRAC: blood clots with Janssen's COVID-19 vaccine
726 [GO] 2021―May―03 Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
727 [GO] 2021―Apr―23 FDA remote evaluation of drug manufacturing during COVID-19
728 [GO] 2021―Apr―23 Health Canada: blood clots with AstraZeneca's COVID-19 vaccine
729 [GO] 2021―Apr―23 Denmark ceases roll out of AstraZeneca's COVID-19 vaccine
730 [GO] 2021―Apr―23 COVID-19 Vaccine Janssen: rare unusual blood clots, low platelets
731 [GO] 2021―Apr―23 PRAC: blood clots or capillary leak syndrome with COVID-19 vaccines
732 [GO] 2021―Apr―23 Health Canada: AKI or ARF with remdesivir for COVID-19?
733 [GO] 2021―Apr―16 Should cancer patients receiving ICIs received COVID-19 vaccination?
734 [GO] 2021―Apr―16 Pfizer-BioNTech COVID-19 vaccine: AEs after vaccination in New Zealand
735 [GO] 2021―Apr―16 AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
736 [GO] 2021―Apr―10 Falsified COVID-19 vaccine recently identified in Mexico
737 [GO] 2021―Apr―10 AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
738 [GO] 2021―Apr―10 AstraZeneca COVID-19 vaccine: no increased rate of VTE
739 [GO] 2021―Apr―02 No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
740 [GO] 2021―Apr―02 Ongoing evaluation of COVID-19 Vaccine AstraZeneca-related blood clots
741 [GO] 2021―Apr―02 AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada
742 [GO] 2021―Mar―26 Universal COVID-19 vaccination cost saving unless anaphylaxis rate high
743 [GO] 2021―Mar―26 Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
744 [GO] 2021―Mar―26 Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
745 [GO] 2021―Mar―26 March 2021 PRAC meeting highlights include COVID-19 vaccine update
746 [GO] 2021―Mar―26 COVID-19-vaccine-Pfizer-BioNTech
747 [GO] 2021―Mar―19 COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis
748 [GO] 2021―Mar―19 Reports of flu-like symptoms after COVID-19 vaccination
749 [GO] 2021―Mar―19 EMA assessing cases of blood clots after AstraZeneca COVID-19 vaccine
750 [GO] 2021―Mar―19 COVID-19 vaccine AE reports in Australia and New Zealand
751 [GO] 2021―Mar―13 Vial and carton labelling updated for Moderna COVID-19 vaccine
752 [GO] 2021―Mar―13 COVID-19 vaccine-related lymphadenopathy may affect breast screening
753 [GO] 2021―Feb―26 COVID-19 vaccine safety monitoring
754 [GO] 2021―Feb―19 Second HPRA safety update on COVID-19 vaccines
755 [GO] 2021―Feb―12 MHRA Yellow Card reports on COVID-19 vaccine adverse reactions
756 [GO] 2021―Feb―12 Safety update on COVID-19 vaccine Comirnaty finds no new concerns
757 [GO] 2021―Feb―05 Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
758 [GO] 2021―Feb―05 WHO considers Pfizer BioNTech COVID-19 vaccine safe in elderly
759 [GO] 2021―Feb―05 HPRA safety update on BioNTech and Moderna COVID-19 vaccines
760 [GO] 2021―Jan―29 Norway advised to assess the very frail prior to COVID-19 vaccination
761 [GO] 2021―Jan―29 Moderna COVID-19 vaccine: 2.5 cases of anaphylaxis per million doses
762 [GO] 2021―Jan―29 ISMP reports: errors or hazards with COVID-19 vaccines
763 [GO] 2021―Jan―29 NSAID use does not increase risk of COVID-19-related death
764 [GO] 2021―Jan―22 Deaths in frail patients after Pfizer/BioNTech COVID-19 vaccination
765 [GO] 2021―Jan―22 Advice on COVID-19 vaccines approved in UK by MHRA
766 [GO] 2021―Jan―22 Safety of COVID-19 vaccines: who should see an allergist
767 [GO] 2021―Jan―21 Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis
768 [GO] 2021―Jan―08 Pfizer COVID-19-related drug use and safety surveillance
769 [GO] 2021―Jan―06 Managing allergic reactions to Pfizer-BioNTech COVID-19 vaccine
770 [GO] 2020―Dec―21 COVID-19-related deaths not increased with ACE inhibitor or ARB use
771 [GO] 2020―Dec―11 EMA and ICMRA urge continuation of COVID-19 vaccine safety trials
772 [GO] 2020―Nov―27 EMA's safety monitoring plan for COVID-19 vaccines
773 [GO] 2020―Nov―20 Drug-drug interactions in patients with COVID-19
774 [GO] 2020―Nov―13 EMA guidance on risk management plans for COVID-19 vaccines reviewed
775 [GO] 2020―Nov―06 Quality of ADR reporting evaluated for remdesivir trials of COVID-19
776 [GO] 2020―Nov―06 Hydroxychloroquine-related psychiatric disorders in COVID-19 patients
777 [GO] 2020―Nov―06 Phase III trial of Covid-19 treatment paused for safety concerns
778 [GO] 2020―Nov―06 Concerns raised with MHRA of anticoagulant use during pandemic
779 [GO] 2020―Oct―16 Remdesivir-related acute kidney injury in patients with COVID-19
780 [GO] 2020―Oct―02 Sex differences in ADR reports for drugs used to treat COVID-19
781 [GO] 2020―Aug―14 Proton pump inhibitors increase risk of COVID-19
782 [GO] 2020―Aug―14 Health Canada approves first drug for treatment of COVID-19
783 [GO] 2020―Jul―24 Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
784 [GO] 2020―Jul―17 Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
785 [GO] 2020―Jun―26 New potential interaction with emergency COVID-19 medicine remdesivir
786 [GO] 2020―Jun―12 Benefit-risk assessment for remdesivir in COVID-19
787 [GO] 2020―Jun―12 Risks of chloroquine or hydroxychloroquine use for COVID-19
788 [GO] 2020―Jun―05 COVID-19 pregnancy prevention guidance on teratogenic drugs
789 [GO] 2020―Jun―05 UK's MHRA publishes guidance for valproate PPP during pandemic
790 [GO] 2020―May―29 Chloroquine and hydroxychloroquine increase risk of death in COVID-19
791 [GO] 2020―May―29 Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic
792 [GO] 2020―May―29 Cardiac adverse reactions with off-label Covid-19 treatments
793 [GO] 2020―May―23 US guidance issued for postmarketing AE reporting during pandemic
794 [GO] 2020―May―18 International Society of Pharmacovigilance: COVID-19 role
795 [GO] 2020―May―18 MHRA COVID-19 website for reporting ADRs and incidents
796 [GO] 2020―May―18 Risk of Covid-19 with renin-angiotensin-aldosterone system medications
797 [GO] 2020―May―11 Evaluation of potential therapies for COVID-19 global pandemic
798 [GO] 2020―May―11 Demand for potentially hazardous COVID-19 treatments
799 [GO] 2020―May―11 UMC: use appropriate COVID-19-related terms for ICSRs
800 [GO] 2020―May―04 ACEI inhibitors and ARBs do not increase severity of COVID-19
801 [GO] 2020―May―04 Safety concerns with higher dosage chloroquine in COVID-19 patients
802 [GO] 2020―May―04 High incidence of ADRs in COVID-19 patients in China
803 [GO] 2020―May―04 Antimalarial use in COVID-19 patients requires close monitoring
804 [GO] 2020―Apr―20 EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic
805 [GO] 2020―Apr―06 Regulatory agencies issue advice on use of NSAIDs for COVID-19

805 Results       Page 1


Last change 2023―Apr―13 19:50:14 UTC

© Daten-Quadrat 2022       Done in 0.060 sec